Tranzyme Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 14

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 2

Tranzyme General Information

Description

Developer of small molecule therapeutics for the treatment of acute and chronic gastrointestinal or GI, motility disorders.

Contact Information

Formerly Known As
Neokimia
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 5001 South Miami Boulevard
  • Suite 300
  • Durham, NC 27703
  • United States
+1 (919)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 5001 South Miami Boulevard
  • Suite 300
  • Durham, NC 27703
  • United States
+1 (919)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tranzyme Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 15-Jul-2013 Completed Clinical Trials - Phase 2
8. IPO 04-Apr-2011 Completed Clinical Trials - Phase 2
7. Mezzanine 31-Dec-2010 Completed Clinical Trials - Phase 3
6. Later Stage VC (Series B) 15-Jun-2010 Completed Generating Revenue
5. Debt - General 01-Jun-2009 Completed Generating Revenue
4. Early Stage VC (Series B) 01-Feb-2008 Completed Generating Revenue
3. Early Stage VC (Series A) 01-Nov-2007 Completed Product Development
2. Early Stage VC (Series A) 13-May-2005 $32.5M $38.5M Completed Product Development
1. Early Stage VC 18-Dec-2003 $6M $6M Completed Startup
To view Tranzyme’s complete valuation and funding history, request access »

Tranzyme Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A1
Series A 69,300,000 $0.000010 $1 $1 1x $1 64.82%
To view Tranzyme’s complete cap table history, request access »

Tranzyme Patents

Tranzyme Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2003217695-A1 Novel trans-viral vectors comprising multicistronic expression constructs and methods of use Inactive 22-Feb-2002
WO-2003072797-A1 Novel trans-viral vectors comprising multicistronic expression constructs and methods of use Inactive 22-Feb-2002
US-20030167500-A1 Integrating nucleotide sequences into genomes of vertebrates by contacting plasma membrane of isolated early stage embryo (fertilized ooctyes) with vector Inactive 21-Dec-2001
AU-2002367024-A1 Methods and compositions for generating a genetically modified animal using lentiviral vectors Inactive 21-Dec-2001
CA-2470527-A1 Methods and compositions for generating a genetically modified animal using lentiviral vectors Inactive 21-Dec-2001 A01K67/0275
To view Tranzyme’s complete patent history, request access »

Tranzyme Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tranzyme Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
BDC Capital Growth/Expansion Minority
Desjardins Capital PE/Buyout Minority
Fonds de solidarite FTQ PE/Buyout Minority
Greer Capital Advisors Venture Capital Minority
H.I.G. HealthBridge Partners Growth/Expansion Minority
You’re viewing 5 of 13 investors. Get the full list »

Tranzyme Acquisitions (1)

Tranzyme’s most recent deal was a Reverse Merger with Ocera Therapeutics. The deal was made on 15-Jul-2013.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ocera Therapeutics 15-Jul-2013 Reverse Merger Biotechnology
To view Tranzyme’s complete acquisitions history, request access »

Tranzyme FAQs

  • When was Tranzyme founded?

    Tranzyme was founded in 1998.

  • Where is Tranzyme headquartered?

    Tranzyme is headquartered in Durham, NC.

  • What is the size of Tranzyme?

    Tranzyme has 14 total employees.

  • What industry is Tranzyme in?

    Tranzyme’s primary industry is Pharmaceuticals.

  • Is Tranzyme a private or public company?

    Tranzyme is a Private company.

  • What is Tranzyme’s current revenue?

    The current revenue for Tranzyme is .

  • How much funding has Tranzyme raised over time?

    Tranzyme has raised $165M.

  • Who are Tranzyme’s investors?

    BDC Capital, Desjardins Capital, Fonds de solidarite FTQ, Greer Capital Advisors, and H.I.G. HealthBridge Partners are 5 of 13 investors who have invested in Tranzyme.

  • When was Tranzyme acquired?

    Tranzyme was acquired on 15-Jul-2013.

  • Who acquired Tranzyme?

    Tranzyme was acquired by Ocera Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process